ATE306928T1 - Fulvestrant formulierung - Google Patents

Fulvestrant formulierung

Info

Publication number
ATE306928T1
ATE306928T1 AT01900186T AT01900186T ATE306928T1 AT E306928 T1 ATE306928 T1 AT E306928T1 AT 01900186 T AT01900186 T AT 01900186T AT 01900186 T AT01900186 T AT 01900186T AT E306928 T1 ATE306928 T1 AT E306928T1
Authority
AT
Austria
Prior art keywords
fulvestrant formulation
fulvestrant
formulation
Prior art date
Application number
AT01900186T
Other languages
English (en)
Inventor
John Raymond Evans
Rosalind Ursula Grundy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26243352&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE306928(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Application granted granted Critical
Publication of ATE306928T1 publication Critical patent/ATE306928T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT01900186T 2000-01-10 2001-01-08 Fulvestrant formulierung ATE306928T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0000313.7A GB0000313D0 (en) 2000-01-10 2000-01-10 Formulation
GBGB0008837.7A GB0008837D0 (en) 2000-01-10 2000-04-12 Formulation
PCT/GB2001/000049 WO2001051056A1 (en) 2000-01-10 2001-01-08 Fulvestrant formulation

Publications (1)

Publication Number Publication Date
ATE306928T1 true ATE306928T1 (de) 2005-11-15

Family

ID=26243352

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01900186T ATE306928T1 (de) 2000-01-10 2001-01-08 Fulvestrant formulierung

Country Status (41)

Country Link
US (5) US20030125387A1 (de)
EP (4) EP2266573B1 (de)
JP (3) JP3713237B2 (de)
KR (1) KR100802366B1 (de)
CN (1) CN1222292C (de)
AR (1) AR027510A1 (de)
AT (1) ATE306928T1 (de)
AU (1) AU762080B2 (de)
BE (1) BE1013477A3 (de)
BG (1) BG65776B1 (de)
BR (1) BR0107445B1 (de)
CA (1) CA2351004C (de)
CH (1) CH696260A5 (de)
CO (1) CO5280206A1 (de)
CY (1) CY1116520T1 (de)
CZ (1) CZ304689B6 (de)
DE (2) DE60114145T3 (de)
DK (2) DK2266573T3 (de)
EE (1) EE05421B1 (de)
EG (1) EG24074A (de)
ES (3) ES2248272T5 (de)
FR (1) FR2803516B1 (de)
GB (3) GB0000313D0 (de)
HK (2) HK1052884B (de)
HU (1) HU230162B1 (de)
IL (2) IL150230A0 (de)
IS (1) IS2932B (de)
IT (2) ITTO20010005A1 (de)
MX (1) MXPA02006698A (de)
MY (1) MY118583A (de)
NL (1) NL1017075C2 (de)
NO (2) NO336286B1 (de)
PL (1) PL202525B1 (de)
PT (2) PT2266573E (de)
RU (1) RU2263507C9 (de)
SI (2) SI1250138T2 (de)
SK (1) SK287221B6 (de)
TW (1) TWI259086B (de)
UA (1) UA75879C2 (de)
WO (1) WO2001051056A1 (de)
ZA (1) ZA200204165B (de)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
IL159576A0 (en) * 2001-07-07 2004-06-01 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0116620D0 (en) * 2001-07-07 2001-08-29 Astrazeneca Ab Formulation
NZ571508A (en) 2002-05-24 2010-05-28 Schering Corp Neutralizing human anti-IGFR antibody
TW200404552A (en) * 2002-05-30 2004-04-01 Akzo Nobel Nv Self administered contraception
US20050152858A1 (en) * 2003-07-11 2005-07-14 Isp Investments Inc. Solubilizing agents for active or functional organic compounds
AR046639A1 (es) * 2003-11-21 2005-12-14 Schering Corp Combinaciones terapeuticas de anticuerpo anti- igfr1
EP1623713A1 (de) * 2004-07-09 2006-02-08 Proskelia SAS Kombinationen von reinen Antiestrogen und Aromataseinhibitoren
EP1879587A2 (de) * 2005-04-15 2008-01-23 Schering Corporation Verfahren und zusammensetzungen zur behandlung oder vorbeugung von krebs
EP1928469A4 (de) * 2005-09-26 2008-12-31 Hospira Australia Pty Ltd Fulvestrant-formulierung
RU2338538C1 (ru) * 2007-02-09 2008-11-20 Государственное учебно-научное учреждение Химический факультет Московского государственного университета им. М.В. Ломоносова Антигипотензивное средство
CN102014925B (zh) 2008-03-07 2013-02-06 赛多斯有限责任公司 氟维司群配制剂
GB0807605D0 (en) 2008-04-28 2008-06-04 Diurnal Ltd Lipid composition
AU2014200332B2 (en) * 2008-04-28 2016-10-06 Diurnal Limited Lipid composition
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
US20100317635A1 (en) 2009-06-16 2010-12-16 Endorecherche, Inc. Treatment of hot flushes, vasomotor symptoms, and night sweats with sex steroid precursors in combination with selective estrogen receptor modulators
ES2627692T3 (es) 2010-06-10 2017-07-31 Aragon Pharmaceuticals, Inc. Moduladores de receptores de estrógenos y usos de los mismos
US8853423B2 (en) 2010-06-17 2014-10-07 Seragon Pharmaceuticals, Inc. Indane estrogen receptor modulators and uses thereof
EA201300341A1 (ru) * 2010-09-16 2013-09-30 Шимода Байотек (Пти) Лтд. Композиция фулвестранта и способы применения
US9029582B2 (en) 2011-05-20 2015-05-12 Capital, Business Y Gestion De Finanzas S.L. Pharmaceutical composition
CN102391341B (zh) * 2011-08-09 2013-05-22 福建省微生物研究所 制备6,7-脱氢-17β-烃酰氧基诺龙的方法
CN103070871B (zh) * 2011-10-26 2015-04-15 正大天晴药业集团股份有限公司 一种氟维司群的药物组合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
EA029559B1 (ru) 2011-12-14 2018-04-30 Серагон Фармасьютикалс, Инк. Фторированные модуляторы рецепторов эстрогенов и их применение
AP2014007657A0 (en) 2011-12-16 2014-05-31 Olema Pharmaceuticals Inc Novel benzopyran compounds, compositions and uses thereof
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
CN102600064A (zh) * 2012-03-31 2012-07-25 西安力邦制药有限公司 氟维司群或其衍生物缓释制剂及其制备方法
WO2013153559A1 (en) * 2012-04-09 2013-10-17 Scidose, Llc Fulvestrant formulations
US11179468B2 (en) 2012-04-09 2021-11-23 Eagle Pharmaceuticals, Inc. Fulvestrant formulations
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
WO2014169462A1 (zh) 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法
US10392667B2 (en) 2013-06-07 2019-08-27 Medical Prognosis Institute A/S Methods and devices for predicting treatment efficacy of fulvestrant in cancer patients
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
WO2014203129A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Combinations of benzopyran compounds, compositions and uses thereof
CN104337761B (zh) * 2013-08-07 2019-03-26 江苏豪森药业集团有限公司 氟维司群药物组合物
JP2016529308A (ja) * 2013-09-06 2016-09-23 サラー ウッディン アハメド， フルベストラント組成物
US9271990B2 (en) 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations
SG11201607334YA (en) 2014-03-13 2016-10-28 Hoffmann La Roche Therapeutic combinations with estrogen receptor modulators
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
KR20250044939A (ko) 2014-12-18 2025-04-01 에프. 호프만-라 로슈 아게 테트라하이드로-피리도[3,4-b]인돌 에스트로겐 수용체 조절제 및 이의 용도
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
LT3355884T (lt) 2015-10-01 2021-07-26 Olema Pharmaceuticals, Inc. Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai
WO2017064639A1 (en) 2015-10-13 2017-04-20 Themis Medicare Limited Fulvestrant compositions
EP3386968B1 (de) 2015-12-09 2025-04-02 The Board of Trustees of the University of Illinois Benzothiophenbasierte selektive östrogenrezeptor-herunterregulierende präparate
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
WO2017175810A1 (ja) * 2016-04-06 2017-10-12 富士フイルム株式会社 医薬組成物
EP3440067B1 (de) 2016-04-08 2021-05-26 F. Hoffmann-La Roche AG Tetrahydroisochinolin-östrogen-rezeptor-modulatoren und deren verwendungen
US11590077B2 (en) 2016-05-06 2023-02-28 Eagle Pharmaceuticals, Inc. Fulvestrant formulations and methods of their use
IL285928B2 (en) * 2016-05-06 2025-06-01 Eagle Pharmaceuticals Inc Fulvestrant formulations and methods of their use
CN109152785B (zh) * 2016-05-31 2021-02-09 富士胶片株式会社 医药组合物
WO2017216280A1 (en) 2016-06-16 2017-12-21 F. Hoffmann-La Roche Ag TETRAHYDRO-PYRIDO[3,4-b]INDOLE ESTROGEN RECEPTOR MODULATORS AND USES THEREOF
CN109311876B (zh) * 2016-06-16 2022-05-03 豪夫迈·罗氏有限公司 杂芳基雌激素受体调节剂及其用途
US20180002344A1 (en) 2016-06-16 2018-01-04 Genentech, Inc. Heteroaryl estrogen receptor modulators and uses thereof
CN107789320B (zh) * 2016-08-31 2021-06-22 鲁南制药集团股份有限公司 一种氟维司群缓释注射液及其制备工艺
CN116832020A (zh) 2017-09-11 2023-10-03 阿托萨治疗学公司 制备和使用内昔芬的方法
BR112020009141A2 (pt) 2017-11-08 2020-10-27 Eagle Pharmaceuticals, Inc. método para tratar câncer de mama num indivíduo
RU2020119578A (ru) 2017-11-16 2021-12-17 Новартис Аг Комбинированные терапии
CN111465398A (zh) * 2018-01-31 2020-07-28 富士胶片株式会社 注射用制剂的制造方法
RU2684330C1 (ru) * 2018-02-02 2019-04-08 Закрытое Акционерное Общество "Биокад" Композиции фулвестранта
US20210253626A1 (en) 2018-05-24 2021-08-19 Kashiv Biosciences, Llc Prodrugs of fulvestrant
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
CN111035613A (zh) * 2018-10-12 2020-04-21 江苏恒瑞医药股份有限公司 一种包含氟维司群的可注射的药物组合物及其制备方法
US20210401859A1 (en) 2018-11-01 2021-12-30 Syros Pharmaceuticals, Inc. Methods of treating cancer in biomarker-identified patients with non-covalent inhibitors of cyclin-dependent kinase 7 (cdk7)
CN113271945A (zh) 2018-12-20 2021-08-17 诺华股份有限公司 包含3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物的给药方案和药物组合
JP7483732B2 (ja) 2019-02-15 2024-05-15 ノバルティス アーゲー ３－（１－オキソ－５－（ピペリジン－４－イル）イソインドリン－２－イル）ピペリジン－２，６－ジオン誘導体及びその使用
EP3924055B1 (de) 2019-02-15 2024-04-03 Novartis AG Substituierte 3-(1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivate und verwendungen davon
UY38700A (es) 2019-05-20 2020-12-31 Novartis Ag Conjugados de anticuerpo-fármaco inhibidores de mcl-1 y sus métodos de uso
JP7662204B2 (ja) 2019-07-03 2025-04-15 アトッサ・セラピューティクス・インコーポレイテッド エンドキシフェンの徐放性組成物
CA3144791A1 (en) 2019-07-07 2021-01-14 Olema Pharmaceuticals, Inc. Regimens of estrogen receptor antagonists
RU2722988C1 (ru) * 2019-11-19 2020-06-05 федеральное государственное бюджетное образовательное учреждение высшего образования "Башкирский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ моделирования проканцерогенного действия фулвестранта на яичники потомства женского пола у лабораторных мышей
US12377049B2 (en) 2019-12-11 2025-08-05 Shanghai Bocimed Pharmaceutical Co., Ltd. Fulvestrant pharmaceutical composition, preparation method therefor, and application thereof
TW202135859A (zh) 2019-12-20 2021-10-01 瑞士商諾華公司 組合療法
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
KR20230027056A (ko) 2020-06-23 2023-02-27 노파르티스 아게 3-(1-옥소이소인돌린-2-일)피페리딘-2,6-디온 유도체를 포함하는 투약 요법
US20230271940A1 (en) 2020-08-03 2023-08-31 Novartis Ag Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
US20240042051A1 (en) 2020-11-24 2024-02-08 Francesca Rocchetti Mcl-1 inhibitor antibody-drug conjugates and methods of use
US11999786B2 (en) 2020-11-24 2024-06-04 Novartis Ag Anti-CD48 antibodies, antibody drug conjugates, and uses thereof
KR20230170644A (ko) 2021-02-02 2023-12-19 르 라보레또레 쎄르비에르 선택적 bcl-xl protac 화합물 및 사용 방법
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
AR125874A1 (es) 2021-05-18 2023-08-23 Novartis Ag Terapias de combinación
JP2024545690A (ja) * 2021-12-20 2024-12-10 サムヤン、ホールディングス、コーポレーション 溶解度が改善されたフルベストラントの医薬組成物及びその製造方法
WO2023225320A1 (en) 2022-05-20 2023-11-23 Novartis Ag Epha2 bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
US20250339547A1 (en) 2022-05-20 2025-11-06 Novartis Ag Met bcl-xl inhibitor antibody-drug conjugates and methods of use thereof
CN120752058A (zh) 2023-03-10 2025-10-03 诺华股份有限公司 panRAS抑制剂抗体-药物缀合物及其使用方法
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
WO2025215536A1 (en) 2024-04-10 2025-10-16 Novartis Ag Macrocyclic panras inhibitors for the treatment of cancer

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB817241A (en) 1957-08-21 1959-07-29 Vismara Francesco Spa Oily solutions for parenteral administration containing adreno-cortical hormones
FR6241E (fr) 1905-04-19 1906-10-10 Ktiengesellschaft Système de refroidissement du piston des moteurs à explosions et des compresseurs
DE947335C (de) 1954-10-19 1956-08-16 Schering Ag Verfahren zur Herstellung stabiler oeliger Loesungen von Oestron
US2983649A (en) 1957-10-15 1961-05-09 Francesco Vismara Societa Per Ricinoleic acid ester solutions of adreno-cortical hormones
GB1060632A (en) * 1962-09-11 1967-03-08 Olin Mathieson Steroid compositions
US3164520A (en) * 1962-10-29 1965-01-05 Olin Mathieson Injectable steroid compositions containing at least 75% benzyl benzoate
JPS4327327Y1 (de) 1965-01-07 1968-11-12
NL151903B (nl) 1965-03-24 1977-01-17 Schering Ag Werkwijze ter bereiding van een injectievloeistof door een steroid op te lossen in een mengsel van ricinusolie en benzylbenzoaat.
USRE28690E (en) * 1965-05-05 1976-01-20 Schering Aktiengesellschaft 17α-Ethinyl-18-methyl-19-nortestosterone esters
GB1207571A (en) * 1967-01-13 1970-10-07 Takeda Chemical Industries Ltd Injectable composition
SU549118A1 (ru) 1973-04-02 1977-03-05 Способ синхронизации половой охоты у циклирующих свиноматок
SU676284A1 (ru) 1975-06-26 1979-07-30 Научно-Исследовательский Институт Животноводства Способ синхронизации половой охоты у самок домашних животных
DE2548413A1 (de) 1975-10-27 1977-04-28 Schering Ag Depotpraeparate in oeliger ungesaettigter loesung zur intramuskulaeren injektion
US4048309A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid ointment formulations
US4048310A (en) 1976-02-24 1977-09-13 E. R. Squibb & Sons, Inc. Topical steroid formulation in form of lotion or cream
NL7711916A (nl) 1977-10-29 1979-05-02 Akzo Nv Werkwijze ter bereiding van sterk geconcen- treerde farmaceutische preparaten van steroiden.
DE2907460A1 (de) * 1978-03-07 1979-09-13 Sandoz Ag Neue resorbierbare galenische kompositionen
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
DE3708942A1 (de) 1987-03-18 1988-09-29 Schering Ag 19,11ss-ueberbrueckte steroide, deren herstellung und diese enthaltende pharmazeutische praeparate
EP0310542B1 (de) * 1987-10-01 1994-06-08 Schering Aktiengesellschaft Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
DE3733478A1 (de) 1987-10-01 1989-04-13 Schering Ag Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
GB8813353D0 (en) * 1988-06-06 1988-07-13 Ici Plc Therapeutic product
JPH04327327A (ja) 1991-04-25 1992-11-16 Toyoda Gosei Co Ltd スリーブとホースの加締め用ダイス
CN1102095A (zh) 1993-10-30 1995-05-03 浙江医科大学 长效雄激素类制剂——十一酸睾丸注射液
IL111991A (en) 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
ZA9510926B (en) * 1994-12-23 1996-07-03 Schering Ag Compounds with progesterone-antagonistic and antiestrogenic action to be used together for female contraception
US20010006963A1 (en) 1995-03-16 2001-07-05 Ursula Lachnit-Fixson Once-a-month injection as a depot contraceptive and for hormone replacement therapy for perimenopausal and premenopausal women
DE19510861A1 (de) 1995-03-16 1996-09-19 Schering Ag Einmonatsspritze als Depot-Kontrazeptivum und für die Hormonersatztherapie für peri- und praemenopausale Frauen
EP0760237A1 (de) 1995-08-30 1997-03-05 Cipla Limited Öl-in-Wasser-Mikroemulsionen
GB9525194D0 (en) * 1995-12-12 1996-02-07 Zeneca Ltd Pharmaceutical composition
JPH09208496A (ja) * 1996-01-30 1997-08-12 Takeda Chem Ind Ltd Ｌｈ−ｒｈ拮抗物質含有組成物
DE19613972A1 (de) 1996-04-09 1997-10-16 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen auf Basis von Rizinusöl
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
KR980008226A (ko) 1996-07-05 1998-04-30 다케다 쿠니오 시각기능장애의 예방 및 치료제
JPH10203982A (ja) * 1996-07-05 1998-08-04 Takeda Chem Ind Ltd 視機能障害の予防・治療剤
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
DE19638045A1 (de) 1996-09-18 1998-03-19 Bayer Ag Injektionsformulierungen von Avermectinen und Milbemycinen
JPH10152438A (ja) * 1996-11-22 1998-06-09 Takeda Chem Ind Ltd １−アザキサントン誘導体またはその塩の安定化方法および１−アザキサントン誘導体含有組成物
JPH11158200A (ja) * 1997-09-26 1999-06-15 Takeda Chem Ind Ltd ヒト成長ホルモン・亜鉛複合体及びその用途
US6191107B1 (en) 1997-09-26 2001-02-20 Takeda Chemical Industries, Ltd. Complex of human growth hormone and zinc
KR100499438B1 (ko) 1997-12-03 2005-07-07 머크 앤드 캄파니 인코포레이티드 수소화 피마자유를 함유하는 지속성 주사제
EP1985285A3 (de) 1999-04-01 2009-08-12 Hana Biosciences, Inc. Zusammensetzungen und Verfahren zur Behandlung von Lymphomen
GB0000313D0 (en) * 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP4327327B2 (ja) 2000-04-03 2009-09-09 ロボテック株式会社 固定スプレー揺動装置
IL159576A0 (en) 2001-07-07 2004-06-01 Astrazeneca Ab Pharmaceutical formulation for the intramuscular administration of fulvestrant
GB0912999D0 (en) 2009-07-27 2009-09-02 Astrazeneca Ab Method-803

Also Published As

Publication number Publication date
US20050043285A1 (en) 2005-02-24
HK1049286A1 (en) 2003-05-09
BR0107445B1 (pt) 2012-10-30
US20030125387A1 (en) 2003-07-03
HU230162B1 (hu) 2015-09-28
EP1250138B2 (de) 2015-07-08
AR027510A1 (es) 2003-04-02
RU2263507C9 (ru) 2020-07-28
US6774122B2 (en) 2004-08-10
US20120329766A1 (en) 2012-12-27
FR2803516A1 (fr) 2001-07-13
NL1017075C2 (nl) 2001-09-25
EP2266573A1 (de) 2010-12-29
SI1250138T1 (sl) 2006-02-28
MXPA02006698A (es) 2002-09-30
SI1250138T2 (sl) 2015-09-30
NO337329B1 (no) 2016-03-14
ES2248272T5 (es) 2015-08-19
HK1052884A1 (en) 2003-10-03
HUP0204137A3 (en) 2005-03-29
ITTO20010005A0 (it) 2001-01-09
ITTO20010008A0 (it) 2001-01-10
IL150230A0 (en) 2002-12-01
JP3713237B2 (ja) 2005-11-09
ES2248272T3 (es) 2006-03-16
EP2286818A1 (de) 2011-02-23
HK1052884B (zh) 2006-07-14
UA75879C2 (en) 2006-06-15
SK287221B6 (sk) 2010-03-08
US8466139B2 (en) 2013-06-18
NO20150741L (no) 2002-07-03
RU2002121507A (ru) 2004-03-20
KR20020073499A (ko) 2002-09-26
DE10100779A1 (de) 2001-07-26
IL150230A (en) 2006-10-31
JP2011190275A (ja) 2011-09-29
HK1150021A1 (en) 2011-10-28
AU2386301A (en) 2001-07-24
IS6454A (is) 2002-07-03
BG106833A (en) 2003-03-31
SK9842002A3 (en) 2003-05-02
RU2263507C2 (ru) 2005-11-10
NO20023227L (no) 2002-07-03
DE60114145D1 (de) 2006-03-02
NO20023227D0 (no) 2002-07-03
EG24074A (en) 2008-05-11
TWI259086B (en) 2006-08-01
ZA200204165B (en) 2003-10-29
PT2266573E (pt) 2015-07-28
GB0000313D0 (en) 2000-03-01
DK1250138T3 (da) 2006-01-23
ES2186517A1 (es) 2003-05-01
EP1669073A2 (de) 2006-06-14
CH696260A5 (de) 2007-03-15
GB0100407D0 (en) 2001-02-21
CZ304689B6 (cs) 2014-09-03
EP2266573B1 (de) 2015-06-17
NO336286B1 (no) 2015-07-13
WO2001051056A1 (en) 2001-07-19
PL356030A1 (en) 2004-06-14
DE60114145T2 (de) 2006-07-13
GB0008837D0 (en) 2000-05-31
GB2359254A (en) 2001-08-22
CN1222292C (zh) 2005-10-12
JP2003519659A (ja) 2003-06-24
US20100152149A1 (en) 2010-06-17
SI2266573T1 (sl) 2015-08-31
JP2004107353A (ja) 2004-04-08
ITTO20010008A1 (it) 2002-07-10
AU762080B2 (en) 2003-06-19
DE60114145T3 (de) 2015-09-17
CO5280206A1 (es) 2003-05-30
US7456160B2 (en) 2008-11-25
CZ20022384A3 (cs) 2002-09-11
NL1017075A1 (nl) 2001-07-11
IS2932B (is) 2015-12-15
EE05421B1 (et) 2011-06-15
DK2266573T3 (en) 2015-07-20
ES2543384T3 (es) 2015-08-18
US20010020016A1 (en) 2001-09-06
CN1394141A (zh) 2003-01-29
ES2186517B2 (es) 2004-03-16
FR2803516B1 (fr) 2003-03-28
CA2351004C (en) 2003-02-18
HUP0204137A2 (hu) 2003-04-28
EP2286818B1 (de) 2020-03-18
EP1250138B1 (de) 2005-10-19
MY118583A (en) 2004-12-31
CA2351004A1 (en) 2001-07-10
HK1049286B (en) 2006-04-07
PT102548A (pt) 2001-07-31
GB2359254B (en) 2002-06-19
BE1013477A3 (fr) 2002-02-05
BR0107445A (pt) 2002-09-17
BG65776B1 (bg) 2009-11-30
CY1116520T1 (el) 2017-03-15
EP1250138A1 (de) 2002-10-23
PL202525B1 (pl) 2009-07-31
EE200200387A (et) 2003-10-15
KR100802366B1 (ko) 2008-02-13
ITTO20010005A1 (it) 2001-07-11
DK1250138T4 (en) 2015-07-27
US8329680B2 (en) 2012-12-11
EP1669073A3 (de) 2008-03-19

Similar Documents

Publication Publication Date Title
ATE306928T1 (de) Fulvestrant formulierung
EP1248673A4 (de) Mischapparat
ATE303787T1 (de) Schergelzusammensetzungen
AR028197A1 (es) Composiciones antitranspirantes
NO20031869L (no) Antiinflammatoriske midler
DE60044147D1 (de) Knetvorrichtung
DE50114386D1 (de) Ng
NO20030917D0 (no) Anvendelse
DE60107598D1 (de) Smart-skin strukturen
DE60125415D1 (de) Formeinsatz
DE50101916D1 (de) Flüssige formulierungen
ATE369830T1 (de) Schweisshemmende zusammensetzungen
ATE314049T1 (de) Schweisshemmende zusammensetzungen
DE60116858D1 (de) Zusammensetzung
DE60122834D1 (de) Torsions-Kipp-Komponente
DE60104126D1 (de) Fungizide formulierung
ATE268116T1 (de) Mesotrion-formulierungen
DE50105875D1 (de) Bauteil
FI20002525A7 (fi) Tulehduksenvastaisia aineita
DE60107312D1 (de) Feste Zusammensetzung
DE50107699D1 (de) Bauelement
ATA12432000A (de) Bauelement
SE9902902D0 (sv) New formulation
UA4611S (uk) Сервірувальний набір
DK1341539T3 (da) Antiinflammatoriske midler

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1250138

Country of ref document: EP